BofA lowered the firm’s price target on Crescent Capital BDC to $19 from $20 and keeps a Buy rating on the shares. Crescent Capital reported another solid quarter following record core earnings last quarter and the firm continues to view Crescent as well-positioned to gain share and deliver attractive risk-adjusted returns, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CCAP: